Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center.
Paolo SolidoroStefania NicolaIrene RidolfiGiorgio Walter CanonicaFrancesco BlasiPierluigi PaggiaroEnrico HefflerDiego BagnascoFilippo PatruccoFulvia RibollaCaterina BuccaGiovanni RollaCarlo AlberaLuisa BrussinoPublished in: Biomedicines (2022)
This real-life study confirms the long-term efficacy of biologics in most SEA patients and indicates that even in non-responders to a first biological drug, it is worth trying a second one. It is hoped that the availability of additional biologics with different targets will help improve the personalization of SEA therapy.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- chronic obstructive pulmonary disease
- prognostic factors
- lung function
- stem cells
- patient reported outcomes
- early onset
- drug induced
- bone marrow
- adverse drug
- air pollution
- electronic health record
- chronic rhinosinusitis